Navigation Links
Study Suggests a Possible Way to Offset Chemobrain Memory Loss
Date:9/5/2008

MORGANTOWN, W.Va., Sept. 5 /PRNewswire-USNewswire/ -- Cancer patients have complained for years about the mental fog known as chemobrain. Now in animal studies at West Virginia University, researchers have discovered that injections of N-acetyl cysteine (NAC), an antioxidant, can prevent the memory loss that breast cancer chemotherapy drugs sometimes induce.

In the WVU researchers' study, published in the September issue of the journal Metabolic Brain Disease, rats were given the commonly used chemotherapy drugs adriamycin and cyclophosphamide. When on the drugs, rats trained to prefer a light room to a dark room forgot their training.

"When animals are treated with chemotherapy drugs, they lose memory," said Gregory Konat, Ph.D., professor of neurobiology and anatomy at WVU. "When we add NAC during treatment, they don't lose memory."

Chosen for its antioxidant properties, NAC is a modified form of the dietary amino acid cysteine.

Jame Abraham, M.D., director of the Comprehensive Breast Cancer Program at WVU's Mary Babb Randolph Cancer Center, said as "chemobrain" entered the national lexicon, many patients expressed frustration about doctors not taking the complaints seriously.

"In the past, there was a lot of ignorance among doctors about chemo-induced cognitive problems," Dr. Abraham said. "In some patients, problems can persist for up to two years."

The WVU authors say as many as 40 percent of cancer patients undergoing chemotherapy complain of symptoms such as severe memory and attention deficits. Previously, scientists suspected the cancer, rather than chemo drugs, might be the cause.

Earlier this year, Dr. Abraham's team of researchers used MRI scans to document the extent of changes to the brain in women who received chemotherapy for breast cancer. Now the connection between drugs and memory loss is clear, and a potential remedy is suggested as well.

"At this point, we have no evidence to say tha
'/>"/>

SOURCE West Virginia University Health Sciences Center
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cytopia Commences Second Phase II Study in Brain Cancer
2. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
3. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
4. CDC Misses Target With Flawed MMR/Autism Study
5. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
6. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
7. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
8. Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis
9. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
10. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
11. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... LONGMONT, Colo. , Aug. 27, 2015 /PRNewswire/ ... focused on the development of Next Generation ... for applications in high speed fiber-optic data ... Michael Lebby has been appointed to ... Lebby,s reputation in the field of optoelectronics is ...
(Date:8/27/2015)... and SOUTH SAN FRANCISCO, Calif. ... Fibrosis Foundation (PFF) and Veracyte, Inc. ... organizations are partnering on a U.S. patient survey ... interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis ... survey will assess the steps and time required ...
(Date:8/27/2015)... , Aug. 27, 2015  QB3@953—a ... a University of California (UC) research institute and ... company GSK to identify and facilitate collaborations to ... benefit patients. The agreement formalizes a ... Academia (DPAc) team and creates a new channel ...
Breaking Medicine Technology:Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2
... 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), ... on cardiac and vascular surgery, announced today that it ... of Vice President, Research and Development; and David P. ... Market Development Surgical Adhesives and Starch Medical Relations.  Dr. ...
... LOUIS, Jan. 4, 2012 Express Scripts now provides ... HealthBridge Pharma & Biotech services. CuraScript, a wholly owned ... suite of services, will be among a limited number ... EYLEA (aflibercept) Injection was approved by the ...
Cached Medicine Technology:CryoLife Enhances Management Team with Promotions 2CryoLife Enhances Management Team with Promotions 3CryoLife Enhances Management Team with Promotions 4CryoLife Enhances Management Team with Promotions 5Express Scripts HealthBridge Pharma & Biotech to Provide Specialty Pharmacy and Specialty Distribution Services for EYLEA™ (aflibercept) Injection 2
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... solutions and creators of CMaps Analytics, announced a new location analytics designer for ... professionals to create a wide range of maps experiences in the cloud and ...
(Date:8/27/2015)... ... August 27, 2015 , ... An inventor from Gibertsville, Pa., knows how knees ... against each other while I’m trying to sleep," he said, "so I decided that ... easy-to-use, ergonomic BTKG BED TIME KNEE GUARD helps a user get a better sleep ...
(Date:8/27/2015)... ... 27, 2015 , ... Doctors in the US, the UK and Switzerland say ... especially if given when cells are in the stage known as autophagy. Surviving Mesothelioma ... full article. , Cancer investigators with the University of California, the University of ...
(Date:8/27/2015)... ... August 27, 2015 , ... Generate fully customizable three dimensional ... within Final Cut Pro X. , With ProGeo Refraction, a FCPX Plugin ... do. Users can generate fully customizable three dimensional geometric shape refraction all within Final ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... After conducting ... Smith, Ephraim McDowell Health in Danville, Ky., has hired Burt Piper, as ... leadership experience, Piper will assume his new duties on September 28. , “Burt is ...
Breaking Medicine News(10 mins):Health News:CMaps Analytics Announces New Location Intelligence Integration for SAP Lumira 2Health News:New Research Unveils Potential Method for Improved Response to Mesothelioma Drug, According to Surviving Mesothelioma 2Health News:Announcing a New FCPX Plugin, ProGeo Refraction from Pixel Film Studios. 2Health News:Ephraim McDowell Health Hires New Chief Operating Officer 2Health News:Ephraim McDowell Health Hires New Chief Operating Officer 3
... of actual resveratrol plus 95% OPCs ... and three ... manufacturer,Renaissance Health Publishing, LLC, is disappointed and confused as to ... of Revatrol, and calls on the for-profit laboratory,to remove the ...
... often be the smarter choice, study suggests , MONDAY, Nov. ... symptoms of throat infection, surgery to remove the tonsils is ... watching and waiting to see if symptoms resolve, a Dutch ... University Medical Center Utrecht compared 151 children, ages 2 to ...
... McCandliss, a psychologist at the Sackler Institute for Developmental ... Weill Cornell Medical College, has received a commendation by ... of a Presidential Early Career Award for Scientists and ... by the U.S. government for outstanding scientists and engineers ...
... new article appearing in American Journal of Transplantation describes ... of organ rejection in kidney transplants. The technique, which ... examining DNA sequences, defines how major causes of organ ... behavior. The study is the first to show how ...
... Booker, II, CPA, Presented with Charles Kopke,Medal ... Nov. 19 The American,Diabetes Association (ADA), ... fight against diabetes, announced today that G. ... Arkansas, received the,Association,s prestigious Charles Kopke Medal ...
... an,important step toward protecting patient access to essential ... Fracture Prevention and,Osteoporosis Testing Act of 2007," sponsored ... a reversal of drastic Medicare cuts,to DXA (dual ... the gold standard for measuring bone mass to ...
Cached Medicine News:Health News:ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing 2Health News:ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing 3Health News:Tonsillectomy Not Always Cost-Effective for Kids' Throat Woes 2Health News:White House awards Weill Cornell's Bruce McCandliss highest honor for early career scientists 2Health News:Breakthrough in organ rejection diagnosis examines gene behavior 2Health News:Bill Booker Receives American Diabetes Association's Distinguished Service Award 2Health News:Bill Booker Receives American Diabetes Association's Distinguished Service Award 3Health News:Congress Moves to Protect Bone Health 2